Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens (Q24644442)

20

Steven A Rosenberg

0 references

John R Wunderlich

11

John Wunderlich

0 references

Udai S Kammula

6

Udai Kammula

0 references

Marybeth S Hughes

4

Marybeth S Hughes

0 references

Carolyn Laurencot

18

Carolyn Laurencot

0 references

Stephanie G Downey

14

Stephanie G Downey

0 references

Jacob A Klapper

16

Jacob Klapper

0 references

Paul F Robbins

7

Paul F Robbins

0 references

author name string

Mark E Dudley

1

0 references

James C Yang

2

0 references

Richard Sherry

3

0 references

Richard Royal

5

0 references

JianPing Huang

8

0 references

Deborah E Citrin

9

0 references

Susan F Leitman

10

0 references

Armen Thomasian

13

0 references

Franz O Smith

15

0 references

Kathleen Morton

17

0 references

Donald E White

Journal of Clinical Oncology

19

0 references

language of work or name

English

0 references

publication date

10 November 2008

0 references

published in

0 references

volume

26

0 references

issue

32

0 references

page(s)

5233-9

0 references

cites work

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652090

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652090

CD8 T cell immunity against a tumor/self-antigen is augmented by CD4 T helper cells and hindered by naturally occurring T regulatory cells.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652090

Cancer immunotherapy: moving beyond current vaccines

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652090

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652090

Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8 T cells via TLR4 signaling.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652090

Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652090

Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652090

Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652090

Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652090

Management of cutaneous melanoma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652090

Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652090

Guidelines for the safe administration of high-dose interleukin-2.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652090

Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652090

The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652090

Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652090

Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma

28 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18809613

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18809613

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2008.16.5449

1 reference

release_yrftnrcbwvd7zfymqs7lzdg5ui

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yrftnrcbwvd7zfymqs7lzdg5ui

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

1 reference

PubMed publication ID

18809613

1 reference